Adipose-derived MSC clusters (S.Biomedics) vs ALF202
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: No discrete molecular target · full Atherosclerotic Cardiovascular Disease pipeline
Adipose-derived MSC clusters (S.Biomedics)
Developed by S.Biomedics
NCT04661644 · Phase 1/2 · completed
This was a single-center, open-label study with no control arm. It treated 20 patients with critical limb ischemia in two sequential dose groups and compared each patient with their own baseline. Ischemic pain scores and pain-free walking distance improved over 24 weeks, while ankle-brachial and toe-brachial index did not change, and only one patient had an ulcer. Because there was no comparator group, there was no formal test against a control, so the result is shown as not applicable. The figures come from the peer-reviewed paper in the International Journal of Stem Cells (2025).
Reported efficacy
Changes in ischemic pain (The degrees of changes in VAS measurement on week 4, week 12, week 24, compared to the baseline.); Changes in pain-free walking distance (The degrees of changes in pain-free walking distance on week 4, week 12, week 24, compared to the baseline.); Changes in TBI (Toe Brachial Index) (The degrees of changes in TBI on week 4, week 12, week 24, compared to the baseline.); Changes in ABI (Ankle Brachial Index) (The degrees of changes in ABI on week 4, week 12, week 24, compared to the baseline.); Change in size of the Ulcer (The degrees of changes in Ulcer size on week 4, week 12, week 24, compared to the baseline.); Determination of maximum tolerable dose according to DLT occurrence (Occurrence of ADR is monitored throughout the baseline to week 4 during phase 1.); Incidence of abnormal laboratory tests results (Laboratory tests are performed on screening(-4~-2 week), baseline, 1 day after the baseline, and on week 4, week 12, week 24, compared to the baseline.); Incidence of abnormal blood pressure (Blood pressure is measured throughout the study (on screening visit(4~2 week before the baseline), base line, a day after the baseline, week 4, 12, 24 compared to the baseline.)); Incidence of abnormal temperature (Temperature is measured throughout the study (on screening visit(4~2 week before the baseline), base line, a day after the baseline, week 4, 12, 24 compared to the baseline.)); Incidence of abnormal physical condition (Examined on every visits, throughout the study (on screening visit(4~2 week before the baseline), base line, a day after the baseline, week 4, 12, 24 compared to the baseline.)): Single-arm study, changes from baseline only (no control group). Ischemic pain VAS (all subjects): 51.00±19.59 mm at baseline to 4.60±7.62 mm at week 24, significant decrease vs baseline at weeks 4, 12 and 24 (p<0.05). Pain-free walking distance: significant increase vs baseline, notably at week 12. ABI and TBI: no significant change vs baseline. Ulcer size: only 1 of 20 patients had an ulcer (130 to 49 mm2 at week 24). (not_applicable)
Result source: NCT04661644
ALF202
Developed by Allife Medical Science and Technology
NCT06359912 · Phase 1 · status unknown
This is a randomized study with a standard-of-care control group, but it is not blinded, enrolls a small number of patients, and its primary focus is safety rather than a disease-specific efficacy outcome; no results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "adverse events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Adipose-derived MSC clusters (S.Biomedics) | ALF202 |
|---|---|---|
| LDL-C, % change | —Not reported | —Not reported |
| Non-HDL-C, % change | —Not reported | —Not reported |
| ApoB, % change | —Not reported | —Not reported |
| Lp(a), % change | —Not reported | —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
LDL-C, % change
- Adipose-derived MSC clusters (S.Biomedics)
- —Not reported
- ALF202
- —Not reported
Non-HDL-C, % change
- Adipose-derived MSC clusters (S.Biomedics)
- —Not reported
- ALF202
- —Not reported
ApoB, % change
- Adipose-derived MSC clusters (S.Biomedics)
- —Not reported
- ALF202
- —Not reported
Lp(a), % change
- Adipose-derived MSC clusters (S.Biomedics)
- —Not reported
- ALF202
- —Not reported
3-point MACE (% with event)
- Adipose-derived MSC clusters (S.Biomedics)
- —Not reported
- ALF202
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ALF202: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Adipose-derived MSC clusters (S.Biomedics)'s landscape · ALF202's landscape